**Abstract:**

**Objective**

We aimed to report the case of a Pakistani female who presented with MMD and hyperthyroidism, and the worldwide literature review of the case reports on MMD associated with hyperthyroidism.

**Methods:**

The study was carried out using PRISMA's recommendations. An electronic search on PubMed, Cochrane Library, and Google Scholar was carried out. Articles explaining the association between Moyamoya disease and thyroid-related diseases were included.

**Results:**

A total of 31 studies were included in the review, with the preponderance of Japanese females. The review has systematically compiled in detail all the aspects of moyamoya syndrome and thyroid disorders- from detailed histories of the included patients to the treatment interventions used and their outcomes.

**Conclusion:**

The authors are with the suggestion that more cases of MMD and its association with other major factors should be presented in Pakistan as well as in all parts of the world.

**Keywords:**Moyamoya disease, thyroid disorders, hyperthyroidism, graves’ disease.

**Key Summary**

* Moyamoya disease (MMD) is a rare progressive vaso-occlusive disorder, characterized by progressive stenosis of terminal portions of internal carotid arteries, anterior portions of the circle of Willis especially, the anterior and middle cerebral arteries.
* We aimed to report the case of a Pakistani female who presented with MMD and hyperthyroidism, and the worldwide literature review of the case reports on MMD associated with hyperthyroidism. The purpose was to compare the MMD management in Pakistan and throughout the world.
* The study was carried out using PRISMA's recommendations. An electronic search on PubMed, Cochrane Library, and Google Scholar was done. The search results were screened according to the study title and abstracts and then according to the full texts.
* Case
* Twenty case reports and eleven literature reviews were selected to add to our study. The review has systematically compiled in detail all the aspects of moyamoya syndrome and thyroid disorders- from detailed histories of the included patients to the treatment interventions used and their outcomes.

**Introduction:**

Moyamoya disease is a rare developing cerebrovascular disorder that involves cerebral arteries which are occluded due to ongoing stenosis1. The word Moya-Moya means a “puff of smoke” in Japanese which was seen during an angiography that is made by the collateral circulation developed to compensate for the blockage in this disease2. The defect can be found in any artery but in some cases, they were found in the median or anterior cerebral artery. It makes an abnormal net-like or fibrous dim-like picture when visualized3. This disease can be found in both adults as well as children and may lead to headaches, seizures, ischemic stroke, intracranial hemorrhage, and transient ischemia attack4. This disease was first described by two renowned scientists named Takeuchi and Shimizu in 19575.

The etiology of this disease is unknown but due early age of onset and the incidence rate found in certain ethnic groups indicate hereditary relation of this disease. The gene of RNF213 was shown to be strongly associated with Moyamoya disease in the population of east Asia6. The factor of finding less prevalence of Moyamoya disease in the white population which carries less common non-Arg4810Lys variants of RNF213 has opened many new avenues of investigation7. Some studies also suggest that circulating angiogenetic factors, such as growth factors, vascular progenitor cells, and cytokines could cause neovascularization by damaging the structures and forming excessive collateral routes and promoting intimal hyperplasia8.

The Moyamoya disease is common in many different races but was first discovered in Japan. Later, China, Korea, and southeastern Asia also reported this disease. An incidence rate of 0.35/100,000 and a prevalence rate of 3.16/100,000 was recorded in Japan in 1995. The prevalence was found more in males comparing it with females with a ratio of 1.8:1. The prevalence of this disease found in China was 3.92/100,000 as reported. No data had clearly shown the incidence of Moyamoya in Europe and the United States, but literature analysis shows that white people have low incidence than Asians, especially Japanese or South Koreans9. It can be said that this disease is familial especially in Japanese as they have a 10.5 higher prevalence rate suggesting genetic factors to be assessed10.

Moyamoya disease has been underreported in Pakistan. In the limited literature on Moyamoya disease, only two case series and a few case reports have been reported. [11, 12, 13, 14] Many studies have reported similar presentations as stroke in a younger population, which raises the question that whether this is underdiagnosed in Pakistan. [15] Additionally, no reports have been found from Pakistan on Moyamoya disease associated with any other disease especially autoimmune, like thyroid abnormalities.

Moyamoya disease has no specific way of treatment but many surgical options such as indirect bypass, and direct bypass and their combination to increase cerebral blood flow have been found to treat ischemic problems16. Surgical Revascularization is considered to prevent further strokes, but it is still controversial to be used to prevent future hemorrhagic stroke in MMD [17]. MMD is a disease that could have an improved prognosis if diagnosed and assessed accurately. The imaging modalities such as conventional computed tomography (CT) and magnetic resonance imaging (MRI), digital subtraction angiography, CT angiography (CTA), and magnetic resonance angiography can be used for diagnosis and help to treat this disease. The cerebral hemodynamics could be evaluated by single-photon emission CT, positron emission tomography, xenon-enhanced CT, perfusion CT, dynamic susceptibility contrast MRI, and arterial spin labeling MRI that could help to measure the parameters hemodynamically [18].

All over the literature, MMD has been described to relate to several systemic diseases for example atherosclerosis, autoimmune diseases, meningitis, brain tumors, and Down syndrome (DS). We aimed to report the case of a Pakistani female who presented with MMD and hyperthyroidism, and the worldwide literature review of the case reports on MMD associated with hyperthyroidism. The purpose was to compare the MMD management in Pakistan and throughout the world

**METHODS**

The study was carried out using PRISMA's recommendations, [19, 20] a comprehensive overview of the main results from the studies performed to evaluate the association between the Moyamoya disease and hyperthyroidism, Graves’ disease, and thyrotoxicosis.

**Literature Search**

An electronic search on PubMed, Cochrane Library, and Google Scholar was done to identify the studies that were published from the inception of the databases. A broad search strategy was deployed, consisting of “Moyamoya, quasi-Moyamoya, Graves’ disease, thyrotoxicosis and thyroid function or thyroid autoantibodies”. All the articles from 1990-2022 were reviewed thoroughly. The same search strategy was used on all the databases.

**Inclusion-Exclusion Criteria**

A comprehensive inclusion-exclusion criterion was designed to omit any sort of confusion for the authors as well as readers. It included

1. Only the published reports were included in the study.

2. Articles published only in the English language were included.

3. Articles explaining the association between the Moyamoya disease and thyroid-related diseases like hyperthyroidism, Grave’s disease, and thyrotoxicosis were included. Those reports which explained other associations of the Moyamoya disease as well were not excluded.

**Data extraction**

Initially, the search results were screened according to the study title and abstracts and then according to the full texts. The selected studies were then scanned according to the inclusion criteria, and the finalized articles were included in this review. Reference lists of relevant articles were also scanned to identify further relevant studies. All the duplicates were removed. Two authors independently screened and extracted the relevant data from the finalized articles. Google spreadsheets were used for the data extraction purpose and tables were made on Microsoft Word.

**Results**

**Case**

A 45-year-old, Pakistani female patient, a known case of poorly controlled hypertension presented with an altered level of consciousness, slurring of speech, vomiting, and headache along with decreased vision in both eyes. A primary health care center referred her to tertiary care hospital in Rawalpindi. Her family revealed having a cerebrovascular accident a week ago. CT angiography of the brain was performed showing marked luminal narrowing of the supra-clinoid segment of the left internal carotid artery, A1 and M1 segments of anterior and middle cerebral arteries with associated extensive serpiginous collateral vessels formation. 2D echo appeared normal having an EF of 60%. The radiographic findings and the neurological symptoms led to a diagnosis of moyamoya disease. Further investigations were carried out to assess any associated Thyroid disorders, as many studies suggested the common association of moyamoya disease and Thyroid disorders. Standard lab tests were done to understand the picture of the thyroid gland.

Blood tests showed Anti Thyroglobulin <20 IU/mL, Anti Thyroid Peroxidase 185 IU/mL, T3 levels 1.29, T4 levels 10.47 & TSH levels 0.96 ulU/ml. Her blood Cp revealed HB 11.1g/dL, WBC 5.1 x 109/uL, PLT 273 x 109/uL, Lymphocytes 37.5% & Granulocytes 53.4%.

She was started on Anti-thyroid drugs, Steroid injections, Antiplatelet, Nymalize (Calcium Channel blocker), Amlodipine Besylate, and Rosuvastatin (Lipid-lowering drug). She was then planned for surgical revascularization.

**Study Selection**

We performed a literature search of different databases (1991-2022) that showed us a result of 1899 articles, after reviewing the titles and abstracts of the articles we were able to seek out 51 articles. We further had to remove 19 articles after a full-length review. Finally, 20 case reports and 11 literature reviews were selected to add to our study.

**Baseline Characteristics**

The total cases presented in this review are 31 (case reports 20, literature reviews 11), with the preponderance of Japanese females, however, Chinese 15, Korean 22, Caucasian 29, Hispanic 29,39 and Asian 33 races were in minority. Overall, the patients' ages ranged from 12-55 years, although, most of them were in their 20s. We considered different characteristics in our study that are summarized in table no.1. Comorbidities were assessed in which we found commonly headaches, [29] Diabetes, [30, 35] DKA, [30] hyperlipidemia, [34] and Grave disease. [44, 47] Some other comorbidities such as Down syndrome was also seen. [38, 39] The patients that have hyperthyroidism are mostly treated with some famous drugs such as propylthiouracil and methimazole which were also used by our patients in this study. [31.33.50.51] They were also found with a combination of drugs named hydrocortisone or insulin in some studies, [30, 35] but the above-mentioned two drugs were common in all. [37, 38, 40] While one study had a history of brompheniramine, and pseudoephedrine used by the patient. [40] When evaluating surgical history, Thyroidectomy was the most common surgery found in most patients in many cases. [34, 36, 37, 40, 46] The vitals were mostly normal where temperature, heart rate, and blood pressure were assessed. The analysis of heart rate showed a range between 90-150 bpm, but one study exceeded 200 bpm. [30] The blood pressure and temperature were mostly normal except in one study where the blood pressure was quite low for both the patients i.e. 32/64 & 50/80. [42] Medical histories mostly manifested hyperthyroidism, grave disease, diabetes mellitus, and Down syndrome, however, some unique disorders such as pheochromocytoma were also observed. [36] The thyroid status in most patients was found to be hyperthyroidism, with only three studies that had hypothyroidism. [34, 37, 40]

**Presenting complaints**

Almost all the patients presented with symptoms that are either related to hyperthyroidism or pointing toward moyamoya disease. Neck swelling (29%) [22, 25, 26, 30, 31, 37, 38, 39, 50] was the predominant complaint, although, excessive sweating (12%), [23, 34, 39, 43] tremors (10%) [23, 25, 49], and exophthalmos (23%) [22, 25, 26, 30, 31, 37, 38, 39, 50] were also frequently reported which indicate the hyperthyroid state. Among the highlighted symptoms of the moyamoya disease reported on the first visit, paralysis (39%) [21, 22, 23, 24, 26, 29, 30, 31, 35, 39, 47, 48] of either the extremity or either half of the body was on the top of the list along with aphasia (16%), [21, 22, 23, 26, 27] weakness (26%) [25, 28, 32, 41, 43, 44, 48, 49] of the face or either of extremity, and sensory symptoms (16%) [23, 25, 27, 38, 40] which include incontinence of urine or feces, numbness in hands were also reported.

**Lab values**

All the patients underwent common basic thyroid lab tests which included TSH (normal value= 0.5 to 5.0 mIU/L), FT3 (normal value= 2.3 to 4.1 pg/mL), and FT4 (normal value= 0.7 to 1.9ng/dL) , were in a hyperthyroid state at the initial testing. However, some studies also mentioned some other tests which were anti-TPO antibody, [21,23,24,25,30,38,43,44] anti-thyroglobulin antibody [13,15,17,24,36,41] thyroid receptor antibody, [21,22,24,29,31,32,33,42,50] and thyroid-stimulating antibody. [22,50]

**Brain imaging findings**

The imaging modalities commonly used were MRI, MRA, ultrasound, and CT, although other techniques like digital subtraction angiography DSA, [28,29] SPECT, [27, 31, 36, 40, 42, 46, 48-50] and positron emission tomography [22] were also sometimes considered to help substantiate the findings. Almost all the studies documented typical moyamoya vessels (stenosis of ICAs) [21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51], occlusion of MCA, [21,22,30,31,33,34,35,37,42,44] and occlusion of ACA. [28,29,34,37,41] Infarctions of different areas of the brain like the lobes of cerebral cortex, and basal ganglia were also commonly reported by the majority of patients.

**Medical and surgical interventions**

All the cases reported in the current study are associated with hyperthyroid states like Graves’ disease, Basedow disease, or thyrotoxicosis, so all of them were initially treated with anti-thyroid therapy to normalize the thyroid levels. However, 5 patients were also treated with beta-blockers along with anti-thyroid medication, [23,28,37,41,48] 2 patients [33, 37] had radioactive therapy, 8 patients [25,30,37,38,41,42,43] used steroids, and 8 patients [24,27,28,32,41,43,44,48] had antiplatelet therapy. 14 patients [23,29,31,34,35,40,42,44,46,47,48,49,50,51] underwent different revascularization surgical procedures like Encephalo-Myo–Synangiosis (EMS) and Encephalo-Duro-Arterio-Synangiosis (EDMS) after the treatment with oral anti-thyroid medication.

**Outcomes**

24 studies reported the outcome out of 31. All of them presented good results except 2 patients who died, both patients experienced sudden death, one from the neurologic cause who was found brain dead after electroencephalogram [45] and another had mixed septic cardiogenic shock and new-onset atrial fibrillation which was the culprit of her death. [48]

**Discussion**

The current review is the only review that explains the case of MoyaMoya Disease (MMD) and its association with common Thyroid disorders in a Pakistani patient. It further correlates the similar cases of MMD diagnosed around the world, the diagnosis, the management of the patients, the interventions used, etc. Upon reviewing an enormous number of cases, it was observed that the disease is more common in adult females, irrespective of race, as is also reported in our case. The reason for including the past medical, drug, and surgical history (table 1) was to understand in-depth if MMD is associated with any sort of pathology that occurred in the past, any surgery that could induce it, or can this disease be the side effect of any drug intervention. This hypothesis was termed false after no regularity was noticed under these three headings when more than 30 published cases were studied. The results are shown in Table 1. The majority of the studies did not report the vitals, likewise, in our case. The few that did, stated increased blood pressure, heart rate, and fever.

Among all the thyroid disorders, graves’ disease was the most common association found with MMD in our review, the results were contradictory to an article, which mentioned the rare association between these two disorders. [52] The current article also explained some rare thyroid associations with MMD like hyperthyroidism, Besdow disease, thyroid tumor, thyrotoxicosis, etc. Thyroid hormones can have a direct effect on the vascular smooth muscle and endothelial cells, [53] this theory suggests atherosclerosis is the common pathology in both thyroid disorders and MMD. Surprisingly, none of the included cases has explained atherosclerosis either in the past medical history of the patients or as one of the associations of MMD. However, two reviews, [34,42] both in their second cases, have stated that hyperlipidemia (a pre- atherosclerotic condition) and transient ischemic attacks a past medical histories of patients. An observational study conducted

in 2016 has also expressed the co-existence of MoyaMoya syndrome and atherosclerosis. [54] According to the guidelines on diagnostic criteria of MMD, patients with cerebral atherosclerosis and pathologic net-like intracranial vessels should be categorized as having MoyaMoya syndrome. [53]

**MMD and hyperhomocysteinemia**

Considering the fact that increased blood homocysteine levels can lead to atherosclerotic and embolic disorders, [56] hyperhomocysteinemia can be the key to diagnosing MMD. Studies have also explained the positive correlation between thyroid hormone T4 and hyperhomocysteinemia. [57,58] Although, a test for blood homocysteine level is not suggested as a primary test during any thyroid disorder diagnosis. A prospective study found hyperhomocysteinemia to be the independent risk factor for MMD. According to the study, serum homocysteine levels are found to be increased in patients with moyamoya syndrome than the patients with non- MMD strokes. [59] This finding has also been proven by the 2 case reports (not included in this article). [60,61] Abnormal Homocysteine level is also noticed to be the cause of middle cerebral artery stenosis, [62] stenotic pathology of this vessel is also commonly observed in MMD. The mechanism of homocysteine on blood vessels is as follows. [63,64] Increased serum homocysteine levels lead to endothelial dysfunction, production of NO is reduced due to reduced endothelial Nitric Oxide Synthase (eNOS), induction of smooth muscle cell escalation, increasing foam cell formation, activation of platelets and coagulation cascade, thrombus formation, reduction in blood vessel size. An Article experimented that pathological homocysteine levels cause endothelial dysfunction in cerebral arterioles at a very low concentration as compared to the same effect produced in the aorta, [65] this explains the vulnerability of cerebral vessels to a very slight change in normal homocysteine value.

**MMD and Inflammatory disease**

Our review included the cases that explained the association of MoyaMoya syndrome with other inflammatory diseases such as polychondritis.[33] Due to insufficient data, the in-depth association between MMD and inflammatory diseases is not understood, however, a published article explained that in a pediatric population, adult-onset autoimmune diseases are linked with MMD. [66] Japanese national survey published in 2014 [67] stated that inflammatory diseases accounted for 17.2% of quasi-MoyaMoya diseases. Among these, hyperthyroidism, auto-immune diseases, and meningitis were in high percentages. Systemic Lupus Erythematosus (SLE), antiphospholipid antibodies syndrome, polyarteritis nodosa, Kawasaki disease, Sjogren’s syndrome, Addison’s disease, myasthenia gravis, polymyositis, Rheumatoid arthritis, thyroiditis, systemic sclerosis, etc. were mentioned in minority. [67,68,69]

**Surgical and Medical Interventions**

Based on the results obtained in table 2, the common medical interventions used for MMD/thyroid disorders were anti-thyroid drug therapy such as Thiamazole (different doses are stated by different studies), anticoagulants like heparin and clopidogrel, NSAIDs- aspirin- to treat inflammation, beta-blockers like metoprolol to control hypertension, glucocorticoids- methylprednisolone- as an anti-inflammation agent. The most common surgical intervention used was indirect revascularization via Encephalo-Duro-Arterial synangiosis, and direct revascularization by superficial temporal artery to middle cerebral artery bypass.

The review of the databases and other google websites was carried out with the intention of discovering any new surgical method that has been or is being designed to treat MMD with a low post-surgical complications rate, we found no such methods. The after-surgery complications of treating moyamoya syndrome using the direct and indirect revascularization methods are reported

by a few articles. [70,71] According to the study, Transient Cheiro-Oral Syndrome (COS) is not rare after surgical revascularization for MMD. [71]

**Limitations and Strengths**

The current review is able to include all the cases explaining the correlations between MMD and thyroid disorders present in the major databases. Following point 3 of the inclusion/exclusion criteria, we were not able to present systematically in detail, the other associations of MMD, for instance, with atherosclerosis, inflammatory diseases, high serum homocysteine levels, etc. however, these associations were covered briefly in the discussion section. Another limitation in the review is, that the case that we presented in the review was not documented with all the aspects included, for example, surgical intervention (if applicable) was not present, and the vitals were not taken. Being the first review to present a Pakistani MMD case is the strength of this review.

**Conclusion**

Comparing a Pakistani case with the other cases has proven the hypothesis that the management of MMD is similar in Pakistan as in other countries. However, the authors are with the suggestion that more cases of MMD and its association with other major factors should be presented in Pakistan as well as in all parts of the world. An in-depth understanding of all the associations may be crucial in formulating a new surgical intervention for MMD with a low rate of post-surgical complications.

**Data Availability Statement**

Data will be available on the request to corresponding author.

**References:**

1. Demartini Z Jr, Teixeira BCA, Cardoso-Demartini AA. Choreoathetosis in Moyamoya Disease. World Neurosurg. 2021 Dec;156:103-104. doi: 10.1016/j.wneu.2021.09.100. Epub 2021 Oct 1. PMID: 34601171.
2. Burkova KI, Azhermacheva MN, Alifirova VM, Alekseeva LN, Zautner NA, Plotnikov DM, Pugachenko NV, Valikova TA. [Moyamoya disease]. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(12):143-147. Russian. doi: 10.17116/jnevro2014114121143-147. PMID: 25726795.
3. Suzuki J, Takaku A. Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol. 1969 Mar;20(3):288-99. doi: 10.1001/archneur.1969.00480090076012. PMID: 5775283.
4. Parray T, Martin TW, Siddiqui S. Moyamoya disease: a review of the disease and anesthetic management. J Neurosurg Anesthesiol. 2011 Apr;23(2):100-9. doi: 10.1097/ANA.0b013e3181f84fac. PMID: 20924291.
5. Oshima H, Katayama Y. Discovery of cerebrovascular moyamoya disease: research during the late 1950s and early 1960s. Childs Nerv Syst. 2012 Apr;28(4):497-500. doi: 10.1007/s00381-012-1708-x. PMID: 22327249.
6. Mertens R, Graupera M, Gerhardt H, Bersano A, Tournier-Lasserve E, Mensah MA, Mundlos S, Vajkoczy P. The Genetic Basis of Moyamoya Disease. Transl Stroke Res. 2022 Feb;13(1):25-45. doi: 10.1007/s12975-021-00940-2. Epub 2021 Sep 16. PMID: 34529262; PMCID: PMC8766392.
7. Ihara M, Yamamoto Y, Hattori Y, Liu W, Kobayashi H, Ishiyama H, Yoshimoto T, Miyawaki S, Clausen T, Bang OY, Steinberg GK, Tournier-Lasserve E, Koizumi A. Moyamoya disease: diagnosis and interventions. Lancet Neurol. 2022 Aug;21(8):747-758. doi: 10.1016/S1474-4422(22)00165-X. Epub 2022 May 20. PMID: 35605621.
8. Fang YC, Wei LF, Hu CJ, Tu YK. Pathological Circulating Factors in Moyamoya Disease. Int J Mol Sci. 2021 Feb 8;22(4):1696. doi: 10.3390/ijms22041696. PMID: 33567654; PMCID: PMC7915927.
9. Huang S, Guo ZN, Shi M, Yang Y, Rao M. Etiology and pathogenesis of Moyamoya Disease: An update on disease prevalence. Int J Stroke. 2017 Apr;12(3):246-253. doi: 10.1177/1747493017694393. Epub 2017 Jan 1. PMID: 28381201.
10. Hertza J, Loughan A, Perna R, Davis AS, Segraves K, Tiberi NL. Moyamoya disease: a review of the literature. Appl Neuropsychol Adult. 2014;21(1):21-7. doi: 10.1080/09084282.2012.721147. Epub 2013 Jun 14. PMID: 24826492.
11. Asumal KB, Akhtar N, Syed NA, Shafqat S, Baig SM. Moyamoya disease: an elusive diagnosis. J Pak Med Assoc. 2003 Apr;53(4):160-2. PMID: 12776902.
12. Ibrahim S, Hyder SS. Moyamoya disease of childhood as a cause of recurrent cerebral ischemic attacks--a case report. J Pak Med Assoc. 1996 Jan;46(1):17-8. PMID: 8830162.
13. Akbar A, Qureshi A, Jooma R. Moyamoya disease presenting with intracranial haemorrhage. J Pak Med Assoc. 1998 Nov;48(11):349-51. PMID: 10323061.
14. Shoukat S, Itrat A, Taqui AM, Zaidi M, Kamal AK. Moyamoya disease: a clinical spectrum, literature review and case series from a tertiary care hospital in Pakistan. BMC Neurol. 2009 Apr 15;9:15. doi: 10.1186/1471-2377-9-15. PMID: 19368734; PMCID: PMC2678270.
15. Razzaq AA, Khan BA, Baig SM. Ischemic stroke in young adults of South Asia. J Pak Med Assoc. 2002 Sep;52(9):417-22. PMID: 12532578.
16. Tokunaga K, Date I. [Moyamoya disease]. Brain Nerve. 2008 Jan;60(1):37-42. Japanese. PMID: 18232331.
17. Mayeku J, Lopez-Gonzalez MA. Current Surgical Options for Moyamoya Disease. Cureus. 2020 Nov 4;12(11):e11332. doi: 10.7759/cureus.11332. PMID: 33173651; PMCID: PMC7647363.
18. Li J, Jin M, Sun X, Li J, Liu Y, Xi Y, Wang Q, Zhao W, Huang Y. Imaging of Moyamoya Disease and Moyamoya Syndrome: Current Status. J Comput Assist Tomogr. 2019 Mar/Apr;43(2):257-263. doi: 10.1097/RCT.0000000000000834. PMID: 30589721; PMCID: PMC642
19. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. bmj. 2021 Mar 29;372.
20. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Systematic reviews. 2021 Dec;10(1):1-1.
21. Gao-Rui C, Guo-Neng C, Wen-Xue J. Aneurysmal bone cyst of the proximal femur concomitant with Graves’ disease and Moyamoya disease: report of a rare case. Journal of International Medical Research. 2022 May;50(5):03000605221097669.
22. Ishigami A, Toyoda K, Suzuki R, Miyashita F, Iihara K, Minematsu K. Neurologic improvement without angiographic improvement after antithyroid therapy in a patient with Moyamoya syndrome. Journal of Stroke and Cerebrovascular Diseases. 2014 May 1;23(5):1256-8.
23. Ren SC, Gao BQ, Yang WL, Feng WX, Xu J, Li SW, Wang YJ. Von Willebrand factor and coagulation factor VIII in Moyamoya disease associated with Graves' disease: A case report. Experimental and Therapeutic Medicine. 2016 Nov 1;12(5):3195-200.
24. Gon Y, Sakaguchi M, Oyama N, Mochizuki H. Diagnostic utility of contrast-enhanced 3D T1-weighted imaging in acute cerebral infarction associated with graves disease. Journal of Stroke and Cerebrovascular Diseases. 2017 Feb 1;26(2):e38-40.
25. Utku U, Asil T, Çelik Y, Tucer D. Reversible MR angiographic findings in a patient with autoimmune Graves disease. American journal of neuroradiology. 2004 Oct 1;25(9):1541-3.
26. Kushima K, Satoh Y, Ban Y, Taniyama M, Ito K, Sugita K. Graves' thyrotoxicosis and Moyamoya disease. Canadian journal of neurological sciences. 1991 May;18(2):140-2.
27. Yamashita S, Tamiya T, Shindo A, Miyake K, Nakamura T, Ogawa D, Kuroda Y, Nagao S. Improvement of Cerebral Arterial Stenosis Associated With Basedow’s Disease—Case Report—. Neurologia medico-chirurgica. 2005;45(11):578-82.
28. Shen A, Ryu S, Lin S. Concurrent moyamoya disease and Graves' thyrotoxicosis: case report and literature review. Acta Neurologica Taiwanica. 2006 Jun 1;15(2):114.
29. Shimogawa T, Morioka T, Sayama T, Hamamura T, Yasuda C, Arakawa S. Champagne bottle neck sign in a patient with Moyamoya syndrome. World Journal of Clinical Cases: WJCC. 2014 Sep 9;2(9):474.
30. Noh BH, Cho SW, Ahn SY. Simultaneous occurrence of diabetic ketoacidosis, thyroid storm, and multiple cerebral infarctions due to Moyamoya disease. Journal of Pediatric Endocrinology and Metabolism. 2016 Feb 1;29(2):221-5.
31. Gill JH, Nam TK, Jung HK, Jang KM, Choi HH, Park YS, Kwon JT. Acute cerebral infarction combined with a thyroid storm in a patient with both Moyamoya syndrome and Graves’ disease. Korean Journal of Cerebrovascular Surgery. 2021 Oct 26.
32. Gill JH, Nam TK, Jung HK, Jang KM, Choi HH, Park YS, Kwon JT. Acute cerebral infarction combined with a thyroid storm in a patient with both Moyamoya syndrome and Graves’ disease. Korean Journal of Cerebrovascular Surgery. 2021 Oct 26.
33. Xuan YY, Li TF, Zhang L, Liu SY. ANCA positive relapsing polychondritis, Graves disease, and suspected moyamoya disease: A case report. Medicine. 2017 Dec;96(51).
34. Tokimura H, Tajitsu K, Takashima H, Hirayama T, Tsuchiya M, Takayama K, Arita K. Familial Moyamoya Disease Associated With Graves' Disease in a Mother and Daughter—Two Case Reports—. Neurologia medico-chirurgica. 2010;50(8):668-74.
35. Suzuki S, Mitsuyama T, Horiba A, Fukushima S, Hashimoto N, Kawamata T. Moyamoya disease complicated by Graves’ disease and type 2 diabetes mellitus: report of two cases. Clinical neurology and neurosurgery. 2011 May 1;113(4):325-9.
36. Matano F, Murai Y, Watanabe A, Shirokane K, Igarashi T, Shimizu K, Shimada T, Morita A. Case Report: A Case of Moyamoya Syndrome Associated With Multiple Endocrine Neoplasia Type 2A. Frontiers in Endocrinology. 2021;12.
37. Tendler BE, Shoukri K, Malchoff C, MacGILLIVRAY DO, Duckrow R, Talmadge T, Ramsby GR. Concurrence of Graves' disease and dysplastic cerebral blood vessels of the moyamoya variety. Thyroid. 1997 Aug;7(4):625-9.
38. Wunderle KB, McCulley C. Smoke and mirrors: Moyamoya syndrome. The American Journal of Medicine. 2017 Sep 1;130(9):1045-8.
39. Tsai M, Tan T, Kuo Y, Chang K. Multiple intracranial arterial stenoses in association with thyrotoxicosis: a case report. Acta Neurologica Taiwanica. 2006 Jun 1;15(2):105.
40. Ohba S, Nakagawa T, Murakami H. Concurrent Graves’ disease and intracranial arterial stenosis/occlusion: special considerations regarding the state of thyroid function, etiology, and treatment. Neurosurgical review. 2011 Jul;34(3):297-304.
41. Malik S, Russman AN, Katramados AM, Silver B, Mitsias PD. Moyamoya syndrome associated with Graves' disease: a case report and review of the literature. Journal of Stroke and Cerebrovascular Diseases. 2011 Nov 1;20(6):528-36.
42. Sasaki T, Nogawa S, Amano T. Co-morbidity of moyamoya disease with Graves' disease. report of three cases and a review of the literature. Internal Medicine. 2006;45(9):649-53.
43. Ito H, Yokoi S, Yokoyama K, Asai T, Uda K, Araki Y, Takasu S, Kobayashi R, Okada H, Okuda S. Progressive stenosis and radiological findings of vasculitis over the entire internal carotid artery in moyomoya vasculopathy associated with graves’ disease: a case report and review o f the literature. BMC neurology. 2019 Dec; 19(1):1-0
44. Golomb MR, Biller J, Smith JL, Edwards-Brown M, Sanchez JC, Nebesio TD, Garg BP. A 10-year-old girl with coexistent moyamoya disease and Graves' disease. Journal of child neurology. 2005 Jul;20(7):620-4.
45. Hsu SW, Chaloupka JC, Fattal DT. Rapidly progressive fatal bihemispheric infarction secondary to Moyamoya syndrome in association with Graves thyrotoxicosis. American journal of neuroradiology. 2006 Mar 1;27(3):643-7.
46. Ohba S, Nakagawa T, Murakami H. Concurrent Graves’ disease and intracranial arterial stenosis/occlusion: special considerations regarding the state of thyroid function, etiology, and treatment. Neurosurgical review. 2011 Jul;34(3):297-304.
47. Choi J, Suthakar P, Farmand F. Fatal outcome in a Hispanic woman with moyamoya syndrome and Graves’ disease. Endocrinology, Diabetes & Metabolism Case Reports. 2016 Nov 4;2016(1).
48. Kamasaki H, Takeuchi T, Mikami T, Komeichi K, Tsutsumi H. A case of graves’ disease diagnosed in the course of bilateral carotid artery stenoses (moyamoya disease); a case report and review of the literature. Clinical Pediatric Endocrinology. 2013;22(3):39-44.
49. Matano F, Murai Y, Adachi K, Kitamura T, Teramoto A. Pathophysiology and management of intracranial arterial stenosis around the circle of Willis associated with hyperthyroidism: case reports and literature review. Neurosurgical review. 2014 Apr;37(2):347-56.
50. Lee R, Sung K, Park YM, Yu JJ, Koh YC, Chung S. A case of Moyamoya disease in a girl with thyrotoxicosis. Yonsei Medical Journal. 2009 Aug 31;50(4):594-8.
51. Nakamura H, Sato K, Yoshimura S, Hayashi Y, Izumo T, Tokunaga Y. Moyamoya disease associated with Graves’ disease and Down syndrome: A case report and literature review. Journal of Stroke and Cerebrovascular Diseases. 2021 Jan 1;30(1):105414.
52. Kainth DS, Chaudhry SA, Kainth HS, et al. Prevalence and characteristics of concurrent down syndrome in patients with moyamoya disease. Neurosurgery 2013;72:210-215. https://doi.org/10.1227/NEU.0- b013e31827b9beb
53. Ojamaa K, Klemperer JD, Klein I. Acute effects of thyroid hormone on vascular smooth muscle. Thyroid 1996;6:505-512.
54. Han C, Li ML, Xu YY, Ye T, Xie CF, Gao S, Duan L, Xu WH. Adult moyamoya-atherosclerosis syndrome: clinical and vessel wall imaging features. Journal of the Neurological Sciences. 2016 Oct 15;369:181-4.
55. on the Pathology RC. Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis). Neurologia medico-chirurgica. 2012;52(5):245-66.
56. Iso H, Moriyama Y, Sato S, et al. Serum total homocysteine concentrations and risk of stroke and its subtypes in Japanese. Circulation 2004;109:2766-2772. https://doi. org/10.1161/01.CIR.0000131942.77635.2D.
57. Colleran KM, Ratliff DM, Burge MR. Potential association of thyrotoxicosis with vitamin B and folate deficiencies, resulting in risk for hyperhomocysteinemia and subsequent thromboembolic events. Endocr Pract 2003;9:290- 295.
58. van Diemen-Steenvoorde R, van Nieuwenhuizen O, de Klerk JB, et al. Quasi-moyamoya disease and heterozygosity for homocystinuria in a five-year-old girl. Neuropediatrics 1990;21:110-112.
59. chrome-extension://dagcmkpagjlhakfdhnbomgmjdpkdklff/enhanced-reader.html?openApp&pdf=http%3A%2F%2Fturkishneurosurgery.org.tr%2Fpdf%2Fpdf\_JTN\_2447.pdf
60. Cerrato P, Grasso M, Lentini A, Destefanis E, Bosco G, Caprioli M, Bradac GB, Bergui M: Atherosclerotic adult moya-moya disease in a patient with hyperhomocysteinaemia. Neurol Sci 28:45-47, 2007
61. Meena DS, Bohra GK, Meena M, Maheshwari BK: Hyperhomocysteinemia in a patient with moyamoya disease. Case Rep Neurol Med 2018:7806873, 2018
62. Huang HW, Guo MH, Lin RJ, Chen YL, Luo Q, Zhang Y, Wong KS: Hyperhomocysteinemia is a risk factor of middle cerebral artery stenosis. J Neurol 254:364-367, 2007
63. An SA, Lee HB, Kim Y, Kim J, Kim HS, Kim WC, Kim OJ, Oh SH: Plasma total homocysteine level is associated with the pulsatility index of cerebral arteries in lacunar infarction. Yonsei Med J 54:819-824, 2013
64. Rueda-Clausen C F, Cordoba-Porras A, Bedoya G, Silva FA, Zarruk JG, López-Jaramillo P, Villa LA: Increased plasma levels of total homocysteine but not asymmetric dimethylarginine in Hispanic subjects with ischemic stroke FREC-VI sub-study. Eur J Neurol 19:417-425, 2012
65. Dayal S, Arning E, Bottiglieri T, Böger RH, Sigmund CD, Faraci FM, et al. Cerebral vascular dysfunction mediated by superoxide in hyperhomocysteinemic mice. *Stroke.* 2004;35:1957–1962.
66. Mejia-Munne JC, Ellis JA, Feldstein NA, Meyers PM, Connolly ES. Moyamoya and inflammation. World neurosurgery. 2017 Apr 1;100:575-8.
67. Hayashi K, Horie N, Izumo T, Nagata I: Nationwide survey on quasi-moyamoya disease in Japan. *Acta Neurochir (Wien)* 156: 935–940, 2014
68. Mejia-Munne JC, Ellis JA, Feldstein NA, Meyers PM, Connolly ES: Moyamoya and inflammation. *World Neurosurg* 100: 575–578, 2017
69. Houkin K, Ito M, Sugiyama T, et al.: Review of past research and current concepts on the etiology of moyamoya disease. *Neurol Med Chir (Tokyo)* 52: 267–277, 2012
70. Araki Y, Uda K, Yokoyama K, Kanamori F, Mamiya T, Nishihori M, Izumi T, Tanahashi K, Sumitomo M, Okamoto S, Wakabayashi T. Surgical designs of revascularization for moyamoya disease: 15 years of experience in a single center. World Neurosurgery. 2020 Jul 1;139:e325-34.
71. Sasamori T, Kuroda S, Nakayama N, Iwasaki Y. Incidence and pathogenesis of transient cheiro-oral syndrome after surgical revascularization for moyamoya disease. Neurosurgery. 2010 Oct 1;67(4):1054-60.

Legends to figure

Figure 1: Prisma Flow Diagram.

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Table 1: Baseline details of the included Case reports and Literature Reviews. | | | | | | | | | | | |
| S. No. | **First author** | **Published year** | **Gender** | **Age** | **Race** | **Comorbid** | **Past drug history** | **Past medical history** | **Past surgical history** | **Thyroid Status** | **Vitals** |
|  | **Case Reports** | | | | | | | | | | |
| 1 | [Cai Gao-Rui](https://pubmed.ncbi.nlm.nih.gov/?term=Gao-Rui%20C%5BAuthor%5D) [13] | 2022 | Female | 25 | None stated | None stated | None stated | Diffuse goiter 3 years back | None stated | Hyperthyroidism | None stated |
| 2 | Akiko Ishigami [14] | 2013 | Female | 22 | Japanese | None stated | None stated | None | None stated | Hyperthyroidism | None stated |
| 3 | SHOU-CHEN REN1 [15] | 2015 | Male | 12 | Chinese | Over activation of factor VIII and von-Willebrand factor | None stated | Suffered with excessive sweating, tremors and irritability | None stated | None stated | None stated |
| 4 | Yasufumi Gon [16] | 2016 | Female | 30 | Japanese | None stated | None stated | Malaise 3 weeks back and Graves disease. | None stated | Hyperthyroidism | None stated |
| 5 | Ufuk Utku [17] | 2004 | Female | 45 | None stated | None stated | None stated | None stated | None stated | Hyperthyroidism | None stated |
| 6 | Kenji Kushima [18] | 1991 | **Case 1:** female.  **Case 2:** female. | **Case** 1: 26. **Case** 2: 22. | **Case 1:** Japanese.  **Case 2:** Japanese. | **Case 1:** None stated. **Case 2:** none stated. | **Case 1:** Anti-thyroid drugs for hyperthyroidism.  **Case 2:** anti-thyroid drug therapy. | **Case 1:** Hyperthyroidism 5 years ago, resolved after taking anti-thyroid drug therapy, Graves’ disease just before moyamoya diagnosis.  **Case 2:** Neck swelling 5 years back, exophthalmos, hyper-hidrosis, and weight loss. Left hemiparesis and motor aphasia at 22 years. | **Case 1:** none stated. **Case 2:** none stated. | **Case 1:** Graves’ disease  **Case 2:** Graves’ disease | **Case 1:** fever (38-39°C)  **Case 2:** None stated |
| 7 | Shiro Yamas [19] | 2005 | Female | 29 | None stated | None stated | None stated | None stated | None stated | Basedow Disease | None stated |
| 8 | Ai-Ling Shen1 [20] | 2006 | Female | 23 | None stated | Migraine like headache | None stated | None stated | None stated | Hyperthyroidism | None stated |
| 9 | Takafumi shimogawa [21] | 2014 | Female | 43 | Japanese | None stated | None stated | None stated | None stated | Hyperthyroidism | None stated |
| 10 | Byoungho H. Noh [22] | 2015 | Female | None stated | None stated | DM 1, DKA | Methimazole (20 mg every 6 h), followed by hydrocortisone (100 mg every 8 h) and 5% Lugol solution (KI 25 mg every 6 h). | None stated | None stated | Hyperthyroidism | HR= 212 beats/min, BP= 130/70 mm Hg fever= 36.3°C. |
| 11 | Chong Kun Cheon [23] | 2014 | **Case 1:** female.  **Case 2:** female. | **Case 1:** 12. **Case 2:** 15. | **Case 1:** None.  **Case 2:** None. | **Case 1:** None stated  **Case 2:** None stated. | **Case 1:** methimazole 20 mg daily.  **Case 2:** 10 mg of methimazole daily. | **Case 1:** Graves’ disease for 10 months.  **Case 2:** Graves’ disease for past 7 years. | **Case 1:** None stated.  **Case 2:** None stated. | **Case 1:** Graves’ disease  **Case 2:** None stated. | **Case 1:** None stated  **Case 2:** None stated |
| 12 | Jong Han Gill [24] | 2021 | Female | 43 | None stated. | None stated. | None stated. | Hyperthyroidism. | None stated. | hyperthyroidism was diagnosed after moyamoya diagnosis. | BP= 175/80 mm/Hg HR= 150 beats/min, fever= 38.5℃. |
| 13 | Yi-Yi Xuan [25] | 2017 | Female | 26 | None stated. | None stated. | PTU. | October 2015, red swelling and pain in both eyes. Several episodes of redness and pain of auricles and eyes bilaterally for 9 months. History of hyperthyroidism, treated with PTU for 8 years. | None stated. | Graves’ disease. | None stated. |
| 14 | Hiroshi Tokimura [26] | 2010 | **Case 1:** female.  **Case 2:** Female. | **Case 1:** 19. **Case 2:** 52. | **Case 1:** Japanese.  **Case 2:** None stated. | **Case 1:** None stated. **Case2:** Hypertension and hyperlipidemia. | **Case 1:** None stated.  **Case 2:** None stated. | **Case 1:** None stated.  **Case 2:** Hypertension, hyperlipidemia, and hyperthyroidism. | **Case 1:** Thyroidectomy. **Case 2:** None. | **Case 1:** hypothyroidism.  **Case 2:** Hyperthyroidism. | **Case 1:** None stated.  **Case 2:** None stated. |
| 15 | Sakiko Suzuki [27] | 2011 | **Case 1:** Male. **Case 2:** Female. | **Case 1:** 38. **Case 2:** 43 | **Case1:** Japanese.  **Case 2 :** Japanese. | **Case 1:** Diabetes mellitus and Autoimmune disease. **Case 2 :** Diabetes mellitus and Grave disease. | **Case 1:** Insulin and thiamazole.  **Case 2:** Insulin and thiamazole. | **Case 1:** Diabetes mellitus and hyperthyroidism.  **Case 2:** Diabetes mellitus and hyperthyroidism. | **Case 1:** None stated.  **Case 2:** None stated. | **Case 1:** Hyperthyroidism.  **Case 2:** Hyperthyroidism. | **Case 1:** None stated  **Case 2:** None stated |
| 16 | Fumihiro Matano [28] | 2021 | Female. | 52. | None stated | Stage T2N1M0 MTC and left-sided pheochromocytoma. | None stated | Pheochromocytoma and stage T2N1M0 MTC. | Thyroidectomy and left central neck D2a dissection. | None stated | None stated |
| 17 | BEATRIZ E. TENDLER, [29] | 1997 | **Case 1:** Female.  **Case2 :** Female. | **Case 1:** 37. **Case 2:** 47 | **Case 1:** Hispanic.  **Case2 :** Caucasian. | **Case 1:** None stated.  **Case 2:** None stated. | **Case 1:** Propylthiouracil 400 mg, and metoprolol 50 mg, later, atenolol 25 mg, propylthyouracil 100 mg, TID and prednisone 30 mg daily.  **Case 2:** atenolol 75 mg, and propylthiouracil 450 mg. Later, propylthiouracil 700 mg/day and preoperative treatment with 5 drops of saturated solution of iodine/day for 7 days, and hydrocortisone 200 mg IV 2 hours. | **Case 1:** Mild episodes of reactive airway disease.  **Case 2:** Dysarthria and accelerated hypertension and episodic reactive airway disease thought to be asthmatic bronchitis with exacerbations. | **Case1:** None Stated.  **Case 2:** Thryoidectomy and angioplasty. | **Case 1:** Hypothyroidism.  **Case 2:** Hypothyroidism. | **Case 1:** BP= 140/90 mm Hg HR=  120 beats per minute .  **Case 2:** None stated. |
| 18 | Kathryn B. [30] | 2017 | Female. | 40. | None stated. | None stated. | Antibiotics and hydroxyzine for tooth ache, anxiety. Current chronic medications included methimazole, atenolol, and insulin for autoimmune diabetes. | One week before, the patient complained of anxiety, light headedness, and tooth pain. The following day she complained of difficulty speaking, vision. Also diagnosed with auto-immune diabetes changes, tongue numbness, and anxiety, the symptoms attributed to a possible drug reaction from either of the 2 newly prescribed medications. | None stated. | Hyperthyroidism. | HR= 127 beats/min, BP= 160/81 mmHg, and fever= 97.7°F. |
| 19 | Meng-Han Tsai, [31] | 2006 | Male. | 26 | None stated. | None stated. | None stated. | None stated. | None stated. | Hyperthyroidism. | BP= 160/90 mmHg HR= 112 beats/minute. |
| 20 | Shigeo ohba [32] | 2011 | Female. | 46 | None stated. | None stated. | Thiamazole and levothyroxine antiplatelet therapy. | Graves’ disease and a thyroid tumor. | Subtotal thyroidectomy. | Hypothyroidism. | None stated. |
|  | **Literature Review** | | | | | | | | | | |
| 1 | Shaneela Malik [33] | 2020 | Female. | 23 | Asian. | Hyperthyroidism. | None stated. | Grave disease. | None stated. | Hyperthyroidism. | None stated. |
| 2 | Takahiro Sasaki [34] | 2006 | **Case 1:** Female.  **Case 2:** Female.  **Case 3:** Female. | **Case 1:** 27  **Case 2:** 16  **Case 3:** 37 | **Case 1:** Japenese  **Case 2:** Japanese  **Case 3:** Japanese | **Case 1:** Hypertension.  **Case 2:** None stated.  **Case 3:** None stated. | **Case 1:** Anti-thyroid therapy.  **Case 2:** None stated.  **Case 3:** Anti-thyroid therapy. | **Case 1:** Graves disease with goiter, bilateral exophthalmos.  **Case 2:** Transient Ischemic Attacks with left hemiparesis and faintness several times for 6 months.  **Case 3:** None stated. | **Case 1:** None stated.  **Case 2:** None stated.  **Case 3:** None stated. | **Case 1:** Hyperthyroidism.  **Case 2:** Hyperthyroidism.  **Case 3:** Graves Disease. | **Case 1:** BP=150/80, HR=116 beats/min. **Case 2:** BP=132/64, HR=80 beats/min.  **Case 3:** None stated. |
| 3 | [Hiroto Ito](https://pubmed.ncbi.nlm.nih.gov/?term=Ito%20H%5BAuthor%5D), [35] | 2019 | Female. | 37 | None stated. | None stated. | None stated. | Asthma. | None stated. | Hyperthyroidism. | None stated. |
| 4 | Chang Y. Tsao [36] | 2004 | Female. | 20 | Caucasian. | Headaches. | brompheniramine and pseudoephedrine. | Increased fatigability, loose stools, episodes of feeling warm over the previous two years, allergies and headaches. | None. | Hyperthyroidism. | BP= 134/80 mm/hg, HR= 120 beats/min. |
| 5 | S.W. Hsu [37] | 2006 | Female. | 40 | None stated. | None stated. | None stated. | Grave disease. | None stated. | Hyperthyroidism. | BP= 210/110 mm/Hg, HR= 97 baets/min. |
| 6 | Shigeo Ohba [38] | 2010 | Female. | 34 | None stated. | None stated. | Thiamazole and levothyroxine and antiplatelet drug. | None stated. | Subtotal thyroidectomy. | Hyperthyroidism. | None stated. |
| 7 | [Julian Choi](https://edm.bioscientifica.com/search?f_0=author&q_0=Julian+Choi) [39] | 2016 | Female. | 31 | Hispanic. | Graves’ disease. | Propranolol and methimazole. | None stated. | None stated. | Hyperthyroidism. | BP= 179/83 mm/Hg, HR= 115 beats/min. |
| 8 | Hotaka Kamasaki [40] | 2013 | Male. | 14 | None stated. | None stated. | None stated. | None stated. | None stated. | Thyrotoxicosis with no specific diagnosis of hyperthyroidism or graves disease. | undocumented slight fever, SBP= 130-160 mm/Hg, HR=120-150 beats/min. |
| 9 | Fumihiro Matano [41] | 2013 | **Case 1:** female.  **Case 3:** female.  **Case 4:** male. | **Case 1:** 32. **Case 3:** 55. **Case 4:** 53. | **Case 1:** none stated.  **Case 3:** None stated. **Case 4:** None stated. | **Case 1:** None stated.  **Case 3:** None stated.  **Case 4:** Hypertension, diabetes, and hyperlipidemia. | **Case 1:** None stated. **Case 3:** None stated. **Case 4:** None stated. | **Case 1:** None stated.  **Case 3:** None stated.  **Case 4:** None stated. | **Case 1:** None stated.  **Case 3:** None stated.  **Case 4:** None stated. | **Case 1:** Hyperthyroidism. **Case 3:** Hyperthyroidism. **Case 4:** Hyperthyroidism. | **Case 1:** BP= 110/60 mmHg.  **Case 3:** 120/70 mm/hg.  **Case 4:** None stated. |
| 10 | Ran lee [42] | 2009 | Female. | 19 | Korean | Down syndrome & Grave disease. | Propylthiouracil. | Down syndrome and grave disease. | None stated. | Hyperthyroidism. | BP= 135/78 mm/Hg, HR=91 beats/min. |
| 11 | Hikaru nakamura [43] | 2021 | Female. | 19 | None stated. | Down syndrome & Grave disease. | Thiamazole. | Down syndrome and grave disease. | None stated. | Normal. | None stated. |
|  |  | | | | | | | | | | |

**Abbreviations: DM= Diabetes Mellitus, DKA= Diabetic Keto-Acidosis, BP= Blood Pressure, HR= Heart rate, PTU= Propylthiouracil, MTC= Medullary Thyroid Carcinoma, TID= Three times per Day.**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table 2: Characteristics of the Case Reports and Literature Reviews.** | | | | | | | | | | | | |
| **S. No** | **First Author** | **Gender** | **Age** | **Lab Values** | **Radiological Findings** | **Genetic Abnormalities** | **Medical Intervention** | **Surgical Intervention** | **Outcomes** | **Symptoms of Moyamoya** | **Symptoms of Thyroid** | **Associations** |
| **Case Reports** | | | | | | | | | | | | |
| **1** | Cai Gao-Rui. | Female. | 25 | TSH (<0.01 mIU/L), T3 (>10 nmol/L), T4 (>320 nmol/L), FT3 (41.1 pmol/L), FT4 (>100 pmol/L), anti-TPO antibody (352 IU/mL), anti-thyroglobulin antibody (3652 IU/mL), and TRAb (14.1 IU/L). | **CT;** bilateral parietal and frontal lobe.  **MRA**;  Multiple cerebral artery stenosis and occlusion of right MCA. | None. | Antithyroid medication. | - | - | Aphasia, flattening of the left  nasolabial fold, and the disability of left upper limb. | - | Graves’ disease. |
| **2** | Akiko Ishigami MD. | Female. | 22 | TSH,.01 mIU/mL, TSH receptor antibody 15.8 IU/L thyroid-stimulating antibody (TS-Ab) 885%, FT3 30.2 pg/mL, FT4 . 7.7 ng/dL. | **MRI**; infarct in the left MCA. **Positron emission tomography**; misery-perfusion phenomenon in the left MCA territory. | none | Edaravone, heparin, and thiamazole | - | Good | Right hemiparesis and sensory loss, left conjugate deviation and aphasia. | Exophthalmos and thyroid lobe enlargement. | Thyrotoxicosis |
| **3** | SHOU-CHEN REN. | Male. | 12 | TSH, <0.001 µU/ml, FT3, 29.17 pmol/l, Positive TR-Ab, TPO-Ab; 396.44 U/ml, and TG-Ab; 134.56 U/ml, TSH, 0.027 µU/ml; FT3, 3.21 pmol/l. | **MRI**; multiple regions of cerebral infarcts, **MRA**; severe stenosis at the bilateral terminal portion of the ICAs, while the bilateral MCAs and ACAs had almost disappeared infarction. | none | 20 mg/day thiamazole, 100 mg/day metoprolol, 30 mg/day Adalat. | Revascularization surgery on the right side, Encephalo‑Duro‑arterial‑synangiosis on the left side. | Good | Rapidly progressive mild quadriplegia, aphasia and urinary incontinence, dysphoric with slurred. | Irritability, tremors, excessive sweating, frequent palpitations and enlarged thyroid gland | Graves’ disease. |
| **4** | Yasufumi Gon MD.,. | Female. | 30 | TSH ≤.010 μU/mL; FT3 ≥25.0 pg/mL; FT4 ≥8.0 ng/dL, TPO-Ab , 87 IU/mL; TR-Ab, 18.5 IU/L. | **US;** distal occlusion pattern in the right ICA artery, **T1WI**; right ICA was thickened, **contrast-enhanced (CE) three-dimensional T1WI**; indicating vasculitis. | None. | Clopidogrel 75 mg/day. | Right superficial temporal artery to middle cerebral artery bypass. | - | Intermittent transient dysarthria and limb shaking of the left leg, paralytic dysarthria, left central facial nerve palsy and left hemiparesis. | General malaise. | Graves’ disease. |
| **5** | Ufuk Utku.. | Female. | 45 | FT3, FT4, TSH, ATG, and anti-TPO 13.8 pg/dL , 5.07 ng/dL , 0.001 IU/mL , 418 IU/mL , and 1000 IU/mL, respectively. | **MRI;** normal,  **CT;** normal, **MRA;** severe stenosis was seen in both distal ICAs and arteries distal to the basilar artery. | None. | Methylprednisolone (1000 mg/day), 20 mg/day prednisolone. | - | - | Drowsiness, hallucinations, and incontinence of urine and feces. Weakness on the right side and dysarthria, experience disorientation. | Fine tremor, minimal exophthalmia, and tachycardi, increase Deep tendon reflexes. | Graves’ disease. |
| **6** | Kenji Kushima. | **Case 1:** female; **Case 2:** female. | **case 1:** 26, **Case 2:** 22 | **Case 1:** T3 7.7 nmol/L,FT4 >66 pmol/L, TSH of < 1.0 mU/L.  **Case 2**: T3 of 5.5 nmol/L, T4 of 265 nmol/L, TSH of 1.0 mU/L.. | **Case 1:**  **CT;** resemblance with A-V malformation and a low-density area in the right frontoparietal region. **Cerebral Angiography;** typical net-like vessels at the base of the brain.  Case 2:  **CT**; low-density areas in the right frontal, temporal and parietal lobes.  **Cerebral angiography;** narrowing of both ICAs, and net-like vessels at the base of the brain. | None, none. | **Case 1:**  Anti-thyroid drug therapy, **Case 2:** anti-thyroid drug therapy. | None. | **Case 1:**Good.  **Case 2:**  Good. | **Case 1:** not mentioned, **Case 2:** left hemiparesis and motor aphasia. | **Case 1**: sensory disturbance in the right upper limb, cramp in the right side face and walking disturbance. **Case 2:** exophthalmos, and a goiter. | **Case 1:**  Graves’ disease.  **Case 2:**  Graves’ disease. |
| **7** | Shiro YAMASHITA. | Female. | 29 | TSH 0.03ng/dl, anti-thyroid globulin antibody 480%. | **MRA;** stenosis of the bilateral distal ICAs and the bilateral proximal ACA and MCA.  **CT and MRI**; normal, **SPECT**; slight reduction in the reserve capacity from the left parietal lobe to the occipital lobe. | - | Thiamazole (15mg/day) and aspirin (81mg/day). | - | Good. | Transient aphasia and numbness in extremities. | Vomiting, diarrhea, and fever over 38 C. | Basedow disease. |
| **8** | Ai-Ling Shen. | Female. | 23 | Triiodothyronine (T3) was 5.76 nmol/L, the free thyroxine (FT4) was > 111 pmol/ , and her thyroid-stimulating hormone (TSH) was < 0.03 mU/ . | **Duplex sonography**; the smaller caliber of the right ICA with reduced volume flow, **MRI;** small infarcts in the right centrum semiovale, **MRA;** segmental narrowing of the right cervical ICA and strictures at the supraclinoid portion of bilateral ICAs,  **DSA**; irregular tubular stenosis of the right cervical ICA and nearly complete occlusion of bilateral supraclinoid ICAs with tortuous collaterals supplying bilateral ACAs and MCAs. | - | Aspirin 100 mg/day, propiothiouracil 150 mg/day and propranolol 30 mg/day, Ticlopidine (250 mg/day) (for the replacement of aspirin). | - | Good. | Weakness and numbness in her left limbs with mildly slurred speech. | Blood pressure was 138/54 mmHg and pulse rate was 113/min, mitral valve prolapse. | Autoimmune thyroid disease. |
| **9** | Takafumi Shimogawa. | Female. | 43 | TSH level of 0.015 μU/mL, FT3 level of 26.42 pg/mL, and FT4 level of 4.37 ng/d,.TSH receptor antibody level was 36.7%. | **MRI;** hyper intense area at the left posterior limb of the internal capsule. **MRA and 3D-CTA**; bilateral severe stenosis of the distal ICA and proximal MCA and ACA, **Digital subtraction angiography**; Moyamoya vessels in the left basal ganglia and bilateral stenosis of the distal ICA and proximal MCA and ACA. | - | - | Encephalo-duro-arterio-synangiosis and encephalo-myo-synangiosis. | Good. | Right hemiparesis and dysarthria. | - | - |
| **10** | Byoungho H. Noh. | Female. | 16 | TSH < 0.001 U/mL, FT4 9.1 ng/dL and T3 7.24 ng/mL,thyroid-stimulating immunoglobulin (16.04 IU/L), anti- TPO-Ab (254.8 U/mL). | **DWI;** revealed multiple acute infarcts on both hemispheres, **MRA;** showed stenosis of both distal ICA, and both M1 portions of the MCA, | - | Methimazole (20 mg every 6 h), hydrocortisone (100 mg every 8 h) and 5% Lugol solution (KI 25 mg every 6 h). | - | Good. | Right hemiplegia | Dehydrated tongue and a grade II goiter. increased appetite and polyphagia feeling hot, sweaty, agitated and confused | DKA, hyperthyroidism, auto-immune thyroiditis, DM 1, DIC |
| **11** | Chong Kun Cheon. | **Case 1**: Female;  **Case 2;**  Female. | **case 1:** 12  **Case2;**  15 | **Case 1:**  T3, FT4, TSH, and TSH receptor antibody; 213.36 ng/dL , 1.64 ng/dL , 0.24 uIU/mL , 112.66 U/L , respectively. **Case 2:**  T3, FT4, TSH, and TSH receptor antibody was 1.07 ng/mL , 0.99 ng/dL , 0.01 uIU/mL , 34.1 U/mL , respectively. | **Case 1:** **MRA, cerebral 4-vessel angiography;** typical stenosis of the right MCA, **SPECT;** cerebral hypo perfusion of the right parietal lobe and decreased vascular reserves of both occipital lobes.  **Case 2: MR;** focal hemorrhage at the left insula, basal ganglia, and focal enhancing nodule, with small collateral vessels in basal ganglia and obliteration of both ICA, **Cerebral angiography;** typical stenosis of the ICA and MCA, **SPECT;** cerebral hypoperfusion of the left parietal lobe, left thalamus, left basal ganglia, and medial temporal lobe without vascular reserve. | - | **Case 1:** Methimazole 20 mg daily, **Case 2:**10 mg of methimazole daily. | **Case 1:** cranial revascularization by encephaloduroarterio-synangiosis (EDAS), **Case 2:** cranial revascularization by EDAS. | Good in both | **Case 1:** syncope with hyperventilation, **Case 2:** right-sided hemiparesis, along with the headache of 3 days' duration. | **Case 1**:-, **Case 2:** goiter and central type sided facial palsy. | **Case 1**: graves disease, **case 2**: graves’ disease. |
| **12** | Jong Han Gill., | Female. | 43 | (TSH)＜0.01 µunits/mL; T3 ＞8.0 ng/mL, FT4 of 9.47 pmol/L ,and TSH receptor antibody of 37.10 U/L . | **MRI=** small cerebral infarction in the left frontal lobe. **2nd MRI;** infarction markedly increased. **Angiography;** revealed occlusion of both distal ICAs, with the characteristics of Moyamoya vessels and poor collateral flow in both frontal lobes. | - | Hydration and antiplatelet therapy, anticonvulsent, amiodarone, beta-blockers, methimazole, Gemstein’s solution, and hydrocortisone. | - | Good. | Weakness in her right side, level of consciousness became stuporous after the anti platelet therapy, seizure. | - | Atrial fibrillation with a rapid ventricular response (RVR), cardiomegaly, hyperthyroidism. |
| **13** | Yi-Yi Xuan. | Female. | 26 | FT3, FT4, TSH; 5.56 (3.28–6.47) pmol/L, 16.75 (7.9–18.4) pmol/L, and 0.01 (0.34–5.6) uIU/mL, respectively. Thyroid hormone antibody (TRAB) was 5.16 (0–1.75) IU/L. | **CT;** multiple ischemic foci in the deep white matter in the left frontal lobe, **MRA;** intracranial segment of the left ICA and the distal segment of the right distal CA were markedly thin, **MRI;** A near-complete occlusion was found in the M1 segment of the right MCA with sparse distal branches. The left posterior cerebral artery was also thin, with sparse distal branches. | - | Prednisone (30 mg/d) and oral CTX (100 mg/d). Iodine-131 (I131) therapy, CTX was stopped and azathioprine ; prednisone was gradually tapered to 7.5 mg/d. | - | Good. | - | - | Graves disease, ANCA positive relapsing polychondritis. |
| **14** | Hiroshi tokimura. | **Case1 :** Female **Case2:** Female | **Case1 :** 19 **Case2** :52 | TSH : 39.51 u/ml FT3: 2.4 pg/dl FT4 : 0.83 ng/dl, | **Cas1:** **MRI;** Infarction in the left parietal lobe, **Cerebral angiography;** Occlusion of terminal portion of the bilateral ICAs and both MCAs and ACAs, **Case2** : **Carotid angiography;** stenosis of terminal portion pf the ICA and ACA and occlusion of the MCA. | - | - | **Case1 :** Revacularization using a spuerficial temporal artery  **Case 2:** STA and MCA anastomosis. | Good. | **Case1:** Dysesthesia of 3rd-5th digits of hands **Case2:** none | **Case1:** Numbness of right hand. **Case 2:** Tachycardia and excessive sweating. | **Case1;** Hypothyroidism **Case2 :** Hyperthyroidism. |
| **15** | Sakiko Suzuki. | **Case1:** Male. **Case2**: Female. | **Case1** : 38 **Case2** :43 | **Case1**: TSH <0.011 IU/ml; FT3 13.08 pg/ml; and FT4 4.81 ng/dl **Case 2 :** TSH <0.010 IU/ml; FT3 20.16 pg/ml; and FT4 7.12 ng/dl. | **Case1 :** **Cerebral angiography;** stenosis of the terminal portion of bilateral ICA and the proximal portion of left MCA, **MRI and MRA;** infarction in the watershed area in the left hemisphere and moyamoya vessels around the circle of Willis  **Case 2 :** **MRI;** cerebral infarction in the deep white matter of the right frontal region .**Cerebral angiography;** stenosis in the terminal portion of right ICA with moyamoya vessels around the circle of Willis. | **-** | **Case 1:** Insulin and thiomazole **Case 2:** insulin and thiamazole. | **Case 1:** Superficial temporal artery (STA)–MCA double bypass on the left side.  **Case2:** STA–MCA double anastomoses on the right side. | - | **Case1:** left radial nerve palsy **Case2:** let hemiparesis of 3/5 MMT | **Case1:** TIA in right upper extremity **Case 2 :** numbness in the left hand. left hemiparesis. | **Graves disease in both cases**. |
| **16** | Fumihiro Matano. | Female. | 52 | - | **MRA;** bilateral supraclinoid stenosis of the ICA decrease CA blood flow. **MRI;** increase in ischemic lesions in the bilateral hemiparesis **DW1;** ischemic lesions in the right hemisphere.  **SPECT;** showed new ischemic lesions in the right hemiparesis. | Heterozygous variant of the RNF213. | Levothyroxine sodium 300 µg/2x and simvastatin 10 mg/2x. | - | - | Bilateral hemiparesis. | - | MEN 2A. |
| **17** | BEATRIZ E. TENDLER. | **Case1:** Female. **Case2:** Female. | **Case1 :** 37 **Case2 :** 47 | **Case1:** TSH <0.1 /iIU/mL, and T4 26.1 µgl L [5.0-10.5] TT3; 289 ng/dL. **Case2:** TSH <0.1 µ /mL, T4 15.9 Ag/dL, TT3 of 289 ng/dL, FTI of 19 and thyroid stimulating immunoglobulin (TSI) of 1,844% of basal activity | **Case1:** **CT;**  localized hypodense area in the right frontal lobe consistent with a right frontoparietal infarct. **Carotid angiogram;** nearly complete occlusion of the right supraclinoid ICA, and tortuous collaterals supplying the territory of both the right MCAs and, to a lesser degree, the right ACAs **Duplex ultrasound;** Nothing found | - | **Case1 :** enteric-coated aspirin, 325 mg/day, propylthiouracil, 100 mg TID, prednisone **Case2 :** radioactive iodine, prednisone 40 mg/day, cholestyramine 3 g/day, and atenolol 75 mg/day. | **Case1** : subtotal thyroidectomy **Case2** : - | Good in both. | **Case1:** paresthesias of the left hand and left arm weakness. **Case2** : diplopia and weight loss. | Lid retraction. A diffusely enlarged thyroid gland. | **Case1;** graves disease  **Case 2**; graves disease. |
| **18** | Kathryn B. | Female. | 40 | TSH < 0.05 mIU/L, FT4 6.39 ng/dL, and TPO-Ab level of 687 IU/mL. | **CT:** bilateral MCA infarcts involving the right frontal lobe and bilateral parietal lobes. **MRA:** revealed extensive narrowing of the bilateral ICA and branches. These findings were suggestive of vasculitis. | - | Steroid. | - | GOOD. | Left-sided facial numbness and cramping, drooling, and aphasia. dizziness, paresthesias, left-sided tingling, and near-syncope. | Exophthalmos and incomprehensible speech. large palpable goiter. | HYPERTHYROIDISM. |
| **19** | Meng-Han Tsai, | MALE. | 26 | FT4: 2.22 ng/dl, T4: 29.6 ug/dl, T3: 486 ng/dl, TSH 0.003 uIU/ml). | **MRI;** infarction at posterior limb of right internal capsule. **Cerebral angiography**; multiple intracranial artery stenosis. **Carotid duplex;** not significant. | - | propylthiouracil (PTU) | - | GOOD. | Episodic transient left hemiparesis and mild slurred speech lasting for few minutes to 2 hours for one month | Heat intolerance, excessive sweating and palpitation, weight loss and hand tremor. Enlarged thyroid gland | GRAVES AND HYPERTHYROID STATE |
| **20** | Shigeo ohba. | FEMALE. | 46 | FT3, FT4, and TSH were 1.1 pg/ml, 0.4 ng/dl, and 53.8 μU/ml, respectively. | **MRI;** lacunar infarction and severe stenosis of both ICAs **MRA;** severe stenosis of the terminal portion of both ICAs. Net-like moyamoya vessels were also detected  **SPECT;** revealed a bilateral decrease in blood flow | - | - | Open surgery with left STA- MCA bypass. Right STA-MCA bypass with encephalomyosynangiosis. | Good | Transient weakness and numbness in her right upper limb, muscle pain, feeling of cold, and weight gain. | - | Graves’ disease, thyroid tumor |
| **Literature Reviews** | | | | | | | | | | | | |
| **1** | Shaneela Malik. | Female. | 23. | TSH level, 0.04 uIU/mL. TPO-Ab.1300 U/mL; normal, ,60 U/mL, FT4; 11.48 ng/dL. | **MRI;** acute ischemic infarctions in the left hemisphere **MRA;** tapering occlusive process of the bilateral intracranial ICAs and significant narrowing of the bilateral proximal PCAs, proximal right MCA, and right ACA **Catheter angiography;** near occlusion of the bilateral carotid  arteries distal to the ophthalmic artery. | - | Atenolol, propylthiouracil, methylprednisone, and aspirin and plasmapheresis.  Left arteriomyodural synangiosis. | | Good. | Right arm weakness, fluctuating confusion, facial numbness, and difficulty with speech. | Exophthalmos. | Grave disease. |
| **2** | Takahiro Sasaki. | **Case1:** Female. **Case2:** Female. **Case3:** Female. | **Case1** : 27 **Case2** : 16 **Case3 :** 36 | **CASE 2;**  TSH, 0.08 μU/ml; fT3 5.5 ng/dl; fT4 1.4 ng/dl; TSH receptor antibody, TRAb 56.4% **CASE 2;** TSH 0.01 μU/ml; fT3 9.4 ng/dl; fT4 3.1 ng/dl.  **CASE 3;** TSH<0.1 μU/ml; fT3 4.0 ng/dl; fT4 1.5 ng/dl; TRAb 2.9%, antithyroglobulin antibody, TGAb <0.3 U/ml, anti-thyroid peroxidase antibody, TPO Ab 65.0 U/ml. | **CASE1;**  **T2WI and MRI;** multiple ischemic lesions in the right upper frontal lobe and in the left paraventricular region, **SPECT;** decreased regional cerebral blood flow in the right MCA region, **Angiography;** long narrowed segments at the cervical portions of both ICAs, **MRI;** hemorrhagic infarction.  **CASE 2:** **MRI and MRA;** cerebral infarction in the right frontal lobe and stenosis of the distal portion of bilateral ICAs, **Angiography =** long narrowed segments at the cervical portions of both ICAs, and occlusion of the right anterior cerebral artery. **CASE 3:** **MRI;** high-density lesions on T2WI in the deep white matter of the left cerebral hemisphere, **SPECT;** decreased regional cerebral blood flow in the left ICA region, **Angiography;** long  narrowed segments at the cervical portions of the left ICA  and perfusion by superficial temporal artery via a trans-dural anastomosis | - | **CASE 1**: anti-thyroid hormone  **CASE 2**; none.  **Case 3**: anti-thyroid medication | **Case 1:** encephalo-duro-arteriosynangiosis (EDAS) **Case2:** encephalo-duro-arteriosynangiosis (EDAS)  **Case 3;** none. | **Case1;** Good.  **Case 2;** good.  **Case 3;** good. | **CASE1;** transient attacks of dizziness and left hemiparesis, dysarthria and headache, exaggerated deep tendon reflexes in the left extremities with a dorsiflexed plantar response on the left **CASE 2;** TIAs **CASE 3;** aphasia,exaggerated deep tendon reflexes in the right extremities with a dorsiflexed plantar response on the right side | - | **Case1;** Grave disease  **Case2;** Grave disease  **Case3;**Grave disease. |
| **3** | Hiroto Ito, | Female. | 37 | levels of fT3, fT4, and TSH; 10.58 pg/mL, 2.70 ng/dL, and 0.01 μU/mL, respectively, anti-TPO Ab, 148.0 IU/mL, TRAb, 8.3 IU/mL | **DWI;** cortical and subcortical infarcts in the left MCA territory, **MRA;** almost-normal cerebral arteries or very mild stenosis of the left ICA, **MRI;** thick vessel walls in the left ICA than in the right on three-dimensional (3D)-  **T1WI AFTER 5 MONTH**; stenosis of the left ICA from the proximal to distal portion and CBN, **MRI;** High-intensity lesion on T1 W1 in the distal portion of the left ICA was observed AFTER 2 YEARS; **catheter angiography**; improved blood flow in the left ACA, MCA, and ICA, as well as mild improvement of stenosis of the terminal portion of the left ICA. | c.14576 G > A (rs112735431) in the RNF-213 gene. | Potassium iodide, heparin, warfarin, argatroban, methylprednisolone (IVMP; 1000 mg/day on days 2–6) clopidogrel (300 mg on day 1, and 75 mg/day from day 2), and aspirin (300 mg on day 1, and 100 mg/day from day 2), Methimazole (15 mg/day), prednisolone (PSL; 1 mg/kg/day),methotrexate (MTX; 4 mg/week) | None stated. | Good. | Progressing weakness of the right arm, mild paralysis of the right arm. | Felt palpitation and sweating at times. | Grave disease |
| **4** | Chang Y. Tsao. | Female. | 10 | T3 570 ng/dL, a fT3 20.3 pg/mL, T4 22.1 g/dL, fT4 8.8 ng/dL, TSH 0.013 IU/mL, thyroidstimulating immunoglobulin 89% , a positive antithyroglobulin antibody of 6.2 U/mL, positive antithyroperoxidase antibody of 28.7 U/mL. | **MRI;** infarction in the right posterior frontal lobe and right anterior parietal lobe as well as a small infarct in the left frontal lobe **MRA;** narrowing of both MCA, the right greater than the left |  | Aspirin and verapamil. | Cranial revascularization by pial synangiosis. | - | Weakness of left side. | Fatigue, loose stools, and episodes of feeling warm. | Grave disease. |
| **5** | S.W. Hsu. | Female. | 40 | F T4, 18 ng/dL; TSH, 0.22 μM/mL. | **Cerebral angiography=** Bilateral distal ICA and proximal MCA and ACA occlusion.  **CT;** multiple areas of cerebral ischemia. | - | - | - | Bad. | - | Nausea, vomiting, tremors,. | Grave disease. |
| **6** | Shigeo Ohba. | Female. | 34. | FT3, fT4, and TSH were 1.1 pg/ml , 0.4 ng/dl , and 53.8 μU/ml, respectively. | **MRI and MRA;** lacunar infarction and severe stenosis of both ICAs, **SPECT;** bilateral decrease in blood flow. | - | Levothyroxine. | left (STA)- MCA bypass. Right STA-MCA bypass with encephalomyosynangiosis | Good. | Transient ischemic attack (TIA). | - | Grave disease. |
| **7** | Ran lee. | Female. | 19 | TSH level 0.001 microunits/mL, T3 level 681 ng/dL, free T4 level 6.0 ng/dL. | **Cerebral angiography;** bilateral occlusion of the ICA around the supraclinoid segment with some collateral vessels. | - | Propylthiouracil. | Cranial revascularization by EDAS and EMS. | Good. | Central type right facial palsy and episodic transient right-side hemiparesis | Diarrhea and a neck mass. | Grave disease. |
| **8** | [Julian Choi](https://edm.bioscientifica.com/search?f_0=author&q_0=Julian+Choi). | Female. | 31 | TSH, <0.005 IU/mL;  T4, 23.07 μg/dL;  Total T3, >651 ng/dL | **CT;** no acute pathology initially, **CTA;**  complete occlusion of left ICA and severe stenosis of right ICA with stenosis of the M1 and A1 segments with posterior communicating arteries supplying bilateral anterior territories, **MRI;** restricted diffusion abnormality in the left frontal cortex with associated abnormal T2 and FLAIR signal changes consistent with an acute left frontal cortical infarction. | - | Popranolol 40 mg po Q8 h, and methimazole 10 mg po Q8 h, and antiplatelet therapy, phenytoin, lorazepem levetiracetam and valproate. | Bilateral frontotemporoparietal craniotomy.  Bilateral EMS. | Bad. | Progressive right-sided weakness, sluggish and unsteady gait, right facial droop, right arm flaccid paralysis, right leg weakness, absent right shoulder shrug, and right-sided hyperreflexia. | Pupils were 3 mm and reactive to light, exophthalmos. | Graves disease. |
| **8** | Hotaka Kamasaki. | Male. | 14 | TSH= less than 0.1 micro IU/ml, FT4= 3.41ng/dl (elevated), FT4=4.31ng/dl, FT3= 10.08 pg/ml, TSH= less than 0.1, TGAb= 33.6 IU/ml, TPOAB=33.6- positive, TRAB=13.3%- negative, TSAB=135%- negative. | **MRI;** small infarct in the left anterior white matter. **SPECT;** decreased blood flow to the left anterior lobe. **MRA;** bilateral carotid stenosis and collaterals. | - | Anti-thyroid therapy: Thiamazole (MM, 20mg/day), Potassium iodide (KI, 200mg/day), bidoprolol fumerate (5 mg/day). | EDAS. | Good. | Weakness of right arm for 12 months, Soft bruise over the cervical vessels. | Fever, HR 120-150, SBP 130-160, mild exopthalmos and a soft goiter, tremor of both hands. | Graves’ disease |
| **9** | Fumihiro Matano. | **Case 1:** female, case 3: female. case 4: male | **Case 1:** 32, **case 3:** 55. **case 4**: 53 | **Case 1:** TSH, 0.116 μU/mL; fT3, 4.98 ng/dL; fT4, 2.47 ng/dL, The TSH receptor antibody 30.7.  **Case 3:** TSH, 0.032 μU/mL; fT3, 5.18 ng/dL; fT4, 2.50 ng/dL. The TSH receptor antibody 15.2 % and TSAb 319 %.  **Case 4:**  TSH, 2.07 μU/mL; fT3, 3.96 ng/dL; fT4, 1.88 ng/dL. TSAb was 189 % (>180 %). | **Case 1:** **MRI;** cerebral infarction in the right frontal lobe, **cerebral angiography;** bilateral ICA stenosis, **SPECT;**  perfusion defect in the right frontal region. **Case 3:** **CT;** intracerebral hemorrhage in the left frontal lobe, **cerebral angiography;**  bilateral ICA stenosis and right ICA aneurysm. Typical net-like moyamoya vessels were observed. **Case 4;** **MRI;** cerebral infarction in the  bilateral frontal lobe, **cerebral angiography;** bilateral  ICA stenosis and typical net-like moyamoya vessels. | - | **Case 1:** Anti-thyroid ttherapy.  **Case 3:** anti-thyroid therapy, **Case 4:** Conservative therapy with somatostatin. | **Case 1:** STA– MCA bypass surgery with encephalogaleasynangiosis and EMS. **Case 3**: none. case 4: none. | **Case 1:** good. **Case3:** good. **Case 4:** good. | **Case 1:** none stated, **Case 3:** right hemiparesis, motor aphasia. | **Case 1;** BP= 110/60, bilateral enlargement of thyroid gland. **Case 3:** blood pressure was 120/70 mmHg. **Case 4:** none stated. | **Case 1:** hyperthyroidism, **Case 3:** hyperthyroidism **Case 4** : hyperthyroidism. |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| **10** | Hikaru nakamura. | Female. | 19. | FT3, FT4, and TSH of 2.91 pg/dL, 1.34 ng/ dL, and 1.048 mlU/mL, respectively | **MRI;**  a cerebral infarction extending from the right occipital lobe to the parietal lobe  an abnormal vascular network at the cerebral basal area and a champagne bottle-like change of the right cervical ICA **SPECT;** decreased resting local cerebral blood flow of up to 65% in the territory of the right MCA as compared to the contralateral side. | - | - | STA-MCA anastomosis and EDMS. | Good. | Sudden left-sided hemiparesis. | Fever, diarrhea, and weight loss. | Grave disease. |
|  | | | | | | | | | | | | |

**Abbreviations: TSH= Thyroid-Stimulating Hormone, FT4= Free Thyroxine, FT3= Free Tri-Iodothyronine, T4= Thyroxine, T3= Tri-Iodothyronine, TR-Ab= Thyrotropin Receptor Antibody, TPO-Ab= Thyroid Peroxidase Antibody, TG-Ab= Thyroglobulin Antibody, ATG= Anti-Thymocyte Globulin, US= Ultrasound, CT= Computed Tomography, 3D-CTA= Three-Dimensional Computed Tomography Angiography, MRI= Magnetic Resonance Imaging, MRA= Magnetic Resonance Angiography, DWI= Diffusion-Weighted Imaging, ICA= Internal Carotid Artery, MCA= Middle Cerebral Artery, ACA= Anterior Cerebral Artery, PCA= Posterior Cerebral Artery, CTX=Cefotaxime, STA-MCA bypass= Superficial Temporal Artery- Middle Cerebral Artery bypass, EDAS= Encephalo-Duro-Arterio-Synangiosis, EMS= Encephalo-Myo-Synangiosis, EDMS= Encephalo-Duro-Myo-Synangiosis.**